Clarity Pharmaceuticals Ltd. · ASX:CU6
Clarity Pharmaceuticals — ShareCafe Hidden Gems Webinar (December 2022)
15 slides from Clarity Pharmaceuticals's conference presentation, Dec 2, 2022
Slide 1: ShareCafe Hidden Gems Webinar
ShareCafe Hidden Gems Webinar Developing the next-generation of radiopharmaceuticals to improve treatment outcomes for children and adults with cancer Dr Alan Taylor, Executive Chairman 2 December 2022
Slide 2: Disclaimer
Disclaimer Introduction No representation, warranty or assurance (express or implied) is given or made in relation to any forward- This presentation has been prepared by Clarity Pharmaceuticals Ltd (ACN 143 005 341) (Clarity or the looking statement by any person (including any of the Limited Partie
Slide 3: Clarity in a nutshell (ASX:CU6)
Clarity in a nutshell (ASX:CU6) Clarity Pharmaceuticals is a clinical stage radiopharmaceutical company developing next-generation products to address the growing need for better diagnostics and treatments in oncology ASX Code: CU6 Proprietary Global leader in Significant supply, • Share Price: $0.9
Slide 4: Radiopharmaceuticals: Market overview
Radiopharmaceuticals: Market overview Global Oncology Market 2021 Global Oncology Market 2031 US$286 Bn US$~25 Bn US$~1.3 Bn US$600 Bn US$6.3 Bn US$35 Bn US$ ~5 Bn US$~10 Bn Global Oncology Global radiopharmaceuticals Radio-diagnostics Radio-therapeutics 2021 2031 Global oncology market US$ 286 Bill
Slide 5: Growth drivers
Growth drivers Radiopharmaceuticals have shown significant growth potential both diagnostically and therapeutically and companies, similar to Clarity, have proven to be very profitable Positive changes have driven Big Pharma interest in the space • Re-imbursement • Novartis • Pricing (Pluvicto >US$
Slide 6: Current industry challenges
Current industry challenges Combined with a history of Creates challenges supply issues for prescribers Additional demands on existing supply as industry grows Work to be done to convince oncologists that there is a safe, dependable and Inability to control Time sensitive reliable source of the enti
Slide 7: Clarity - the perfect pairing to address current challenges
Clarity - the perfect pairing to address current challenges Copper-64 (half-life = 12.7 hours) Copper-67 (half life = 2.6 days) • Mass produced on cyclotrons • Optimal half-life for peptide-based therapy • Every US zip code covered from 1 location • Commercially available high powered rhodotron for
Slide 8: SAR Technology platform
SAR Technology platform SAR Technology Theranostic radiopharmaceuticals have four main elements: a radioisotope, cage, linker Radioisotope and targeting ligand and are administered Copper isotopes used, for example, in Positron Emission Tomography (PET) intravenously Tumour imaging (64Cu) or therapy
Slide 9: Clinical Development
Clinical Development
Slide 10: Clinical development in multiple cancers
Clinical development in multiple cancers Clarity’s products are progressing through sponsored clinical trials in the US and Australia Clinical development pipeline as of 24 November 2022 Note clinical development pipeline is indicative only, subject to review. All US studies are conducted under IND
Slide 11: SAR-bisPSMA
SAR-bisPSMA Targets the Prostate Specific Membrane Antigen SECuRE - Phase I/IIa (PSMA), present in the majority of prostate cancers • Recruitment completed for imaging stage • Advanced to therapy stage with 67Cu SAR-bisPSMA in the US PROPELLER - Phase I • Reached full recruitment in July 2022 • Top-
Slide 12: SAR-Bombesin
SAR-Bombesin Targets the Gastrin Releasing Peptide receptor (GRPr), which is present in a number of cancers, LATEST NEWS including breast and prostate cancers COMBAT- Phase I/II therapy • IND application approval received in November 2022 from the US FDA for 67Cu SAR-BBN in PSMA-negative prostate ca
Slide 13: SARTATE
SARTATE Targets the Somatostatin Receptor 2 (SSTR2), which is present in an aggressive childhood cancer, neuroblastoma, as well as Neuroendocrine Tumours (NETs), among other cancers CL04 - Phase I/IIa • Safety Review Committee recommendation to continue dose escalation phase, opening cohort 3 • Coho
Slide 14: Accelerating clinical progress
Accelerating clinical progress Dx = Diagnostics BBN Tx Tx = Theranostics 1st patient treated SECuRE BBN Tx COBRA BBN Tx US Advance to PSMA Phase III SABRE Open IND Recruitment cohort 2 Pivotal study 50% recruitment BBN Tx US complete PSMA Tx US commences BBN Dx US COBRA PSMA Dx US PSMA Dx US 50% rec
Slide 15: Thank you
Thank you Contact details Dr Alan Taylor Executive Chairman E: alan.taylor@claritypharm.com
Clarity Pharmaceuticals — ShareCafe Hidden Gems Webinar (December 2022) on 6ix